TY - JOUR T1 - Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX<sub>1</sub> Antagonist SB-674042 and the Selective OX<sub>2</sub> Antagonist <em>N</em>-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-<em>N</em>-pyridin-3-ylmethyl-acetamide (EMPA) JF - Molecular Pharmacology JO - Mol Pharmacol SP - 81 LP - 93 DO - 10.1124/mol.110.064584 VL - 78 IS - 1 AU - Pari Malherbe AU - Olivier Roche AU - Anne Marcuz AU - Claudia Kratzeisen AU - Joseph G. Wettstein AU - Caterina Bissantz Y1 - 2010/07/01 UR - http://molpharm.aspetjournals.org/content/78/1/81.abstract N2 - The orexins and their receptors are involved in the regulation of arousal and sleep–wake cycle. Clinical investigation with almorexant has indicated that this dual OX antagonist is efficacious in inducing and maintaining sleep. Using site-directed mutagenesis, β2-adrenergic-based OX1 and OX2 modeling, we have determined important molecular determinants of the ligand-binding pocket of OX1 and OX2. The conserved residues Asp45.51, Trp45.54, Tyr5.38, Phe5.42, Tyr5.47, Tyr6.48, and His7.39 were found to be contributing to both orexin-A-binding sites at OX1 and OX2. Among these critical residues, five (positions 45.51, 45.54, 5.38, 5.42, and 7.39) were located on the C-terminal strand of the second extracellular loop (ECL2b) and in the top of TM domains at the interface to the main binding crevice, thereby suggesting superficial OX receptor interactions of orexin-A. We found that the mutations W214A45.54, Y223A5.38, F227A5.42, Y317A6.48, and H350A7.39 resulted in the complete loss of both [3H]almorexant and [3H]N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA) binding affinities and also blocked their inhibition of orexin-A-evoked [Ca2+]i response at OX2. The crucial residues Gln1263.32, Ala1273.33, Trp20645.54, Tyr2155.38, Phe2195.42, and His3447.39 are shared between almorexant and 1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone (SB-674042) binding sites in OX1. The nonconserved residue at position 3.33 of orexin receptors was identified as occupying a critical position that must be involved in subtype selectivity and also in differentiating two different antagonists for the same receptor. In summary, despite high similarities in the ligand-binding pockets of OX1 and OX2 and numerous aromatic/hydrophobic interactions, the local conformation of helix positions 3.32, 3.33, and 3.36 in transmembrane domain 3 and 45.51 in ECL2b provide the structural basis for pharmacologic selectivity between OX1 and OX2.Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics ER -